Compare BRID & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | PMVP |
|---|---|---|
| Founded | 1932 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 79.5M |
| IPO Year | 1995 | 2020 |
| Metric | BRID | PMVP |
|---|---|---|
| Price | $7.57 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 428.6K |
| Earning Date | 03-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.00 | $0.82 |
| 52 Week High | $8.84 | $1.88 |
| Indicator | BRID | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 44.81 |
| Support Level | $7.39 | $1.26 |
| Resistance Level | $8.06 | $1.50 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 36.22 | 26.92 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.